BIOFIRE® Blood Culture IDentification 2 (BCID2) panel for early adaptation of antimicrobial therapy in adult patients with bloodstream infections: a real-life experience

Diagn Microbiol Infect Dis. 2023 Feb;105(2):115858. doi: 10.1016/j.diagmicrobio.2022.115858. Epub 2022 Nov 11.

Abstract

Our objective was to assess the effectiveness of a multiplex PCR panel for blood culture identification (BCID2) on the implementation of appropriate antimicrobial therapy. We conducted a monocentric pre/post study comparing the time to result from direct microscopic examination (DE) to bacterial identification (BI) in positive blood cultures between 2 different periods: P1 without BCID2 and P2 with BCID2. Appropriate treatments prescribed before DE and after DE / BCID2 and after BI / BCID2 were compared using direct proportion comparison and survival analysis. For mono-microbial bloodstream infections, the proportion of appropriate antimicrobial treatment after DE was 50% in P1 vs. 87.5% after BCID2 in P2 (P < 0.001) for Gram-negative bacteria and 33.0% in P1 vs. 64.4% in P2 (P < 0.01) for Gram-positive bacteria. A significant difference (P = 0.04) was recorded with survival curves for Gram positive bacteria. BCID2 seems effective in reducing the time for prescribing appropriate antimicrobials.

Keywords: Antimicrobial therapy; Bacterial identification; Blood cultures; Multiplex PCR; Rapid diagnostics.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents* / therapeutic use
  • Bacteremia* / diagnosis
  • Bacteremia* / drug therapy
  • Blood Culture
  • Humans
  • Microscopy
  • Multiplex Polymerase Chain Reaction
  • Sepsis*

Substances

  • Anti-Infective Agents
  • Anti-Bacterial Agents